CytomX Therapeutics Inc [CTMX] stock prices are up 0.47% to $2.15 at the moment. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The CTMX shares have gain 1.90% over the last week, with a monthly amount drifted -21.53%, and not seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
On 3, April 2024, CytomX Therapeutics Announces Nomination of Second Clinical Candidate in Broad PROBODY® T-Cell Engaging Bispecific (TCB) Collaboration with Astellas. In a post published today on Yahoo Finance, – Achievement of latest clinical candidate triggers additional $5 million milestone payment to CytomX and is the third milestone achieved in the collaboration to date -.
From an analyst’s perspective:
CytomX Therapeutics Inc [NASDAQ: CTMX] stock has seen the most recent analyst activity on November 14, 2022, when BMO Capital Markets downgraded its rating to a Market Perform and also revised its price target to $2.60 from $3. Previously, Wedbush downgraded its rating to Neutral on July 07, 2022, and dropped its price target to $2. On July 07, 2022, downgrade downgraded it’s rating to Neutral and revised its price target to $1.50 on the stock. Mizuho downgraded its rating to a Neutral and decreased its price target to $4 on July 07, 2022. Jefferies downgraded its rating to a Hold and reduced its price target to $2 on July 07, 2022. BMO Capital Markets started tracking with a Outperform rating for this stock on June 24, 2022, and assigned it a price target of $9. In a note dated January 18, 2022, Barclays upgraded an Overweight rating on this stock but restated the target price of $7.
The stock price of CytomX Therapeutics Inc [CTMX] has been fluctuating between $1.04 and $2.86 over the past year. Currently, Wall Street analysts expect the stock to reach $2.88 within the next 12 months. CytomX Therapeutics Inc [NASDAQ: CTMX] shares were valued at $2.15 at the most recent close of the market. An investor can expect a potential return of 33.95% based on the average CTMX price forecast.
Analyzing the CTMX fundamentals
The CytomX Therapeutics Inc [NASDAQ:CTMX] reported sales of 101.21M for trailing twelve months, representing a surge of 32.22%. Gross Profit Margin for this corporation currently stands at 0.95% with Operating Profit Margin at -0.06%, Pretax Profit Margin comes in at 0.03%, and Net Profit Margin reading is 0.02%. To continue investigating profitability, this company’s Return on Assets is posted at 0.01, Equity is -0.03 and Total Capital is -0.13. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.29.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.09 points at the first support level, and at 2.04 for the second support level. However, for the 1st resistance point, the stock is sitting at 2.19, and for the 2nd resistance point, it is at 2.24.
CytomX Therapeutics Inc [CTMX] reported earnings per share of $0.01 for its fiscal quarter that ended on 12/30/2023. Based on the Wall Street analysts’ estimates, the company was expected to report earnings of -$0.03/share, meaning a difference of $0.04 and a surprise factor of 133.30%. By comparison, the stated earnings for the previous quarter ended on 9/29/2023 were $0.04 per share as compared to estimates of -$0.19 per share, a difference of $0.23 representing a surprise of 121.10%.
Ratios To Look Out For
It’s worth pointing out that CytomX Therapeutics Inc [NASDAQ:CTMX]’s Current Ratio is 1.17. Also, the Quick Ratio is 1.17, while the Cash Ratio stands at 0.11. Considering the valuation of this stock, the price to sales ratio is 1.44.
Transactions by insiders
Recent insider trading involved McCarthy Sean A., CEO, that happened on Mar 19 ’24 when 20223.0 shares were sold. SVP, Chief Scientific Officer, BELVIN MARCIA completed a deal on Mar 19 ’24 to sell 12795.0 shares. Meanwhile, Chief Business Officer Landau Jeffrey B sold 6562.0 shares on Mar 19 ’24.
